Coronavirus Disease 2019 (COVID-19) Clinical Trials – Overview, Landscape, Trial using Vaccines vs. Therapeutics,and Trials Impacted by COVID-19

The purpose of this report is to provide insight into the overall clinical trial landscape for COVID-19 clinical trials, trials using vaccines vs. therapeutics, and trials impacted by COVID-19.

Scope

The clinical trials data used for these analyses were extracted from GlobalData’s Clinical Trials Database. The data included clinical trials that were captured in the database as of April 22, 2021. The trials were analyzed and segmented by all COVID-19 trials, trials using vaccines, trials using therapeutics, and non-COVID-19 trials impacted due to the pandemic. Further analysis was conducted based on multinational vs. single country, clinical trial sites, status, primary endpoint status, terminated trials, phase, sponsor type, and upcoming milestone events.

Reasons to buy

Understand the global COVID-19 landscape

The trends of vaccine COVID-19 clinical trials

The trends of therapeutic COVID-19 clinical trials

A closer look at the impact of the pandemic on non-COVID-19 trials

Table of Contents

Executive Summary

Introduction

Analysis of COVID-19 Clinical Trials

COVID-19 Clinical Trials for Vaccines

COVID-19 Clinical Trials for Therapeutics

Impact of COVID-19 on Clinical Trials

Key Findings

Appendix

List of Tables

List of Tables

Table 1: Top Countries with COVID-19 Key Stats

List of Figures

List of Figures

Figure 1: Impact of COVID-19

Figure 2: Top Countries in COVID-19 Key Stats

Figure 3: Landscape of Pipeline Candidates for COVID-19, by Phase

Figure 4: Landscape of Vaccines Candidates for COVID-19, by Phase

Figure 5: Number of COVID-19 Clinical Trials by Start Date, by Month

Figure 6: Number of COVID-19 Clinical Trials, by Multinational vs. Single Country

Figure 7: Single Country COVID-19 Clinical Trials, By Region & Phase

Figure 8: Multinational Country COVID-19 Clinical Trials, By Region & Phase

Figure 9: COVID-19 Clinical Trial Sites, by Region

Figures 10 & 11: COVID-19 Clinical Trial Sites, by Country & State

Figures 12 & 13: Number of COVID-19 Clinical Trials, by Phase & Status

Figure 14: Endpoint Status for Completed COVID-19 Clinical Trials

Figure 15: Top Reasons for Terminated Trials, by Phase

Figure 16: Top Reason for Terminated Trials, by Sponsor Type

Figure 17: COVID-19 Clinical Trials by Vaccine, by Month

Figures 18 & 19: Vaccine COVID-19 Clinical Trials, by Phase & Status

Figure 20: Vaccine COVID-19 Clinical Trials, by Sponsor Type

Figure 21: Top Industry Sponsors for COVID-19 Vaccine Clinical Trials

Figure 22: Top Non-Industry Sponsors for COVID-19 Vaccine Clinical Trials

Figures 23 & 24: Pfizer/BioNTech’s Tozinameran (Comirnaty), by Status & Phase

Figures 25 & 26: Moderna’s mRNA-1273, by Status & Phase

Figures 27 & 28: Johnson & Johnson’s JNJ-78436735, by Status & Phase

Figures 29 & 30: AstraZeneca’s Covishield (Vaxzevria), by Status & Phase

Figures 31 & 32: Bharat Biotech’s Covaxin, by Status & Phase

Figures 33 & 34: CanSino Biologics’ Convidecia, by Status & Phase

Figures 35 & 36: SinoVac Biotech’s CoronaVac, by Status & Phase

Figure 37: Upcoming Filings and Regulatory Approvals for COVID-19 Vaccines

Figure 38: Clinical Trial Start Date to First Approval for Vaccines

Figure 39: COVID-19 Therapeutic Clinical Trials, by Month

Figure 40 & 41: Therapeutic COVID-19 Clinical Trials, by Phase & Status

Figure 42: Therapeutic COVID-19 Clinical Trials, by Sponsor Type

Figure 43: Top Industry Sponsors for COVID-19 Therapeutic Clinical Trials

Figure 44: Top Non-Industry Sponsors for COVID-19 Therapeutic Clinical Trials

Figures 45 & 46: Gilead Sciences’ Remdesivir (Veklury), by Status & Phase

Figures 47 & 48: Fujifim Toyama Chemical’s Favipiravir, by Status & Phase

Figures 49 & 50: Eli Lilly’s Bamlanivimab, by Status & Phase

Figures 51 & 52: Regeneron’s Casirivimab + Imdevimab, by Status & Phase

Figures 53 & 54: Eli Lilly’s Baricitinib, by Status & Phase

Figures 55 & 56: CytoDyn’s Leronlimab, by Status & Phase

Figure 57: Upcoming Filings and Regulatory Approvals for Therapeutic COVID-19 Drugs

Figure 58: Clinical Trials Disrupted Due to COVID-19

Figures 59 & 60: Disrupted Clinical Trials, by Reason

Figure 61 & 62: Disrupted Clinical Trials, by Therapy Area

Figure 63: Disrupted Clinical Trials Activities

Figure 64: Disrupted Clinical Trials, by Top Sponsors

Figure 65: Resumed Clinical Trials, by Top Five Therapy Areas

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports